Clinical Trial Update: NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating NovoTTF-100A (tumor treating fields) combined with bevacizumab in recurrent glioblastoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Glioblastoma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• NovoTTF-100A (Tumor Treating Fields therapy)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2025-02-17